

BIOGEN IDEC INC

Form 3

October 21, 2005

**FORM 3****UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB  
Number: 3235-0104Expires: January 31,  
2005Estimated average  
burden hours per  
response... 0.5**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF  
SECURITIES**Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting  
Person \*

Â Hamm Robert A

(Last)

(First)

(Middle)

2. Date of Event Requiring  
Statement

(Month/Day/Year)

10/11/2005

3. Issuer Name **and** Ticker or Trading Symbol  
BIOGEN IDEC INC [BIIB]4. Relationship of Reporting  
Person(s) to Issuer5. If Amendment, Date Original  
Filed(Month/Day/Year)BIOGEN IDEC INC.,Â 14  
CAMBRIDGE CENTER

(Street)

(Check all applicable)

☐ Director ☐ 10% Owner☒ Officer ☐ Other

(give title below) (specify below)

SVP, Immunology Business Unit

6. Individual or Joint/Group

Filing(Check Applicable Line)

☒ Form filed by One Reporting

Person

☐ Form filed by More than One  
Reporting Person

CAMBRIDGE,Â MAÂ 02142

(City)

(State)

(Zip)

**Table I - Non-Derivative Securities Beneficially Owned**1. Title of Security  
(Instr. 4)2. Amount of Securities  
Beneficially Owned  
(Instr. 4)3. Ownership  
Form:  
Direct (D)  
or Indirect  
(I)  
(Instr. 5)4. Nature of Indirect Beneficial  
Ownership  
(Instr. 5)

Common Stock

9,494.434 <sup>(1)</sup>

D

Â

Reminder: Report on a separate line for each class of securities beneficially  
owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of  
information contained in this form are not  
required to respond unless the form displays a  
currently valid OMB control number.****Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**1. Title of Derivative Security  
(Instr. 4)2. Date Exercisable and  
Expiration Date  
(Month/Day/Year)

Date Exercisable

3. Title and Amount of  
Securities Underlying  
Derivative Security  
(Instr. 4)

Title

4. Conversion  
or Exercise  
Price of  
Derivative  
Security5. Ownership  
Form of  
Derivative  
Security:  
Direct (D)6. Nature of  
Indirect Beneficial  
Ownership  
(Instr. 5)

# Edgar Filing: BIOGEN IDEC INC - Form 3

	Expiration Date		Amount or Number of Shares		or Indirect (I) (Instr. 5)	
Stock Option (right-to-buy) <sup>(2)</sup>	12/09/2000 <sup>(3)</sup>	12/09/2009	Common Stock	28,750	\$ 62.28	D    Â
Stock Option (right-to-buy) <sup>(2)</sup>	12/15/2001 <sup>(4)</sup>	12/15/2010	Common Stock	5,750	\$ 45.46	D    Â
Stock Option (right-to-buy) <sup>(2)</sup>	12/14/2002 <sup>(5)</sup>	12/14/2011	Common Stock	10,062	\$ 49.03	D    Â
Stock Option (right-to-buy) <sup>(2)</sup>	12/06/2003 <sup>(6)</sup>	12/06/2012	Common Stock	20,124	\$ 37.45	D    Â
Stock Option (right-to-buy) <sup>(2)</sup>	12/31/2004 <sup>(7)</sup>	02/06/2014	Common Stock	27,475	\$ 43.45	D    Â
Stock Option (right-to-buy) <sup>(2)</sup>	02/17/2006 <sup>(8)</sup>	02/17/2015	Common Stock	45,000	\$ 67.57	D    Â

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Hamm Robert A BIOGEN IDEC INC. 14 CAMBRIDGE CENTER CAMBRIDGE, MA 02142	Â	Â	Â SVP, Immunology Business Unit	Â

## Signatures

By: Benjamin S. Harshbarger; For: Robert Hamm 10/21/2005

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) Number of directly held shares consists of 336,434 shares acquired through the Issuer's Employee Stock Purchase Plan and a grant 9158 shares of Restricted Stock which fully vest on 02/06/2007.
- (2) Granted under one of the Issuer's stock option plans, in an exempt transaction under SEC rule 16(b)-3(d).
- (3) The stock option became exercisable in five (5) equal annual installments, commencing one year after the grant date of 12/09/99.
- (4) The stock option becomes exercisable in five (5) equal annual installments, commencing one year after the grant date of 12/15/00.
- (5) The stock option became exercisable in four (4) equal annual installments, commencing one year after the grant date of 12/14/01.
- (6) The stock option became exercisable in four (4) equal annual installments, commencing one year after the grant date of 12/06/02.
- (7) The stock option becomes exercisable in four (4) equal annual installments on 12/31/04, 12/31/05, 12/31/06 and 12/31/07.
- (8) The stock option becomes exercisable in four (4) equal annual installments, commencing one year after the grant date of 02/17/05.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.